COMPANY PROFILE

BridGene Biosciences

Explore full profile

Biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules

San Jose, United StatesFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About BridGene Biosciences

BridGene Biosciences, Inc. is a biotechnology company based in Sunnyvale, CA, specializing in the discovery of novel drug targets and the development of new therapeutics for unmet medical needs. The company employs a proprietary chemoproteomic platform called IMTAC™ to develop covalent drugs for high-value, hard-to-drug targets, including those involving protein-protein interactions or shallow binding pockets. This platform integrates advanced technologies such as covalent chemistry, chemical proteomics, and quantitative mass spectrometry. BridGene also utilizes a Target-Oriented Discovery approach, leveraging its industry-leading expertise to identify and develop new drug candidates.

The company primarily serves pharmaceutical and biotechnology firms looking for innovative solutions to complex medical challenges. Operating in the highly competitive biotechnology market, BridGene's business model focuses on research and development, partnering with other companies for drug development, and potentially licensing its proprietary technologies. Revenue is generated through these partnerships, licensing agreements, and milestone payments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: San Jose, United States
Employees: 31
Open positions: None listed
Dealroom signal: 83.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Oct 2025	$28M	$193M	ShenZhen GTJA Investment Group · Proxima Ventures · Lapam Capital · Grains Valley Venture Capital	↗
SERIES BOther financing	Jul 2022	$39M	$154M	Junson Capital · Dyee Capital · Lapam Capital	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

BridGene Biosciences website traffic

Latest recorded traffic for BridGene Biosciences is 2.5K monthly website visits, up 19% over the last three months. BridGene Biosciences's team grew 47.6% over the past year.

Latest monthly visits2.5K 3-month web change+19% 1-year team growth+47.6%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STSOLID TherapeuticsSOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen	Copenhagen, Denmark	Operational	5	—	—
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational
MBMonod BioDevelops biosensors intended for protein and other analyte detection	Seattle, United States	Operational
CTCimeio TherapeuticsDeveloping Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases	Cambridge, United States	Operational
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational